To strengthen the disease prevention for Beijing citizens, the government in Beijing introduced for the first time a campaign to absorb the costs for people to get vaccinated against influenza. In November 2007, the public bidding started, where the government offered to buy 2.8 million doses of influenza vaccine for 0.1 billion RMB.
Altogether, 10 companies joined the bidding and 5 companies won.
Among them Sanofi Pasteur and 4 other Chinese Influenza Vaccine manufacturers, one of them being Tianyuan.
Tianyuan's flu vaccine occupies more than half of the domestic supply for Beijing's senior citizens.
At the end of November, over 430,000 human doses have been vaccinated with no occurrence of any adverse reaction.
Influenza is an infection of the respiratory tract caused by influenza virus. It involves a combination of respiratory (cough, sore throat) and constitutional (fever, headache, muscle aches) symptoms. In Children, older adults and people with a range of pre-existing medical conditions influenza infections can lead to serious and even life threatening complications.
As the circulating viruses change by mutation infections can occur repeatedly throughout life and protection by vaccination requires annual dosing with updated vaccines. Seasonal vaccination prevents influenza and reduces the impact of epidemics.
Tianyuan's influenza vaccine YUGANNING is an inactivated split vaccine, produced on embryonated chicken eggs. The vaccine is manufactured according to the seasonal WHO recommendation for Northern and Southern Hemisphere. The vaccine's quality level is comparable to internationally available vaccines. Tianyuan aspires to get the WHO pre-qualification status for YUGANNING.